(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the ...

Researchers reviewed a host of studies investigating diet plans in an effort to guide evidence-based recommendations for ...

Pronounced “soh-TIK-too,” SOTYKTU is a once-daily pill for adults with moderate to severe plaque psoriasis that works inside ...

Improvements in Scalp Itch-Numeric Rating Scale (SI-NRS) were greater in the roflumilast group than for the vehicle group, ...

In type 1 diabetes, the body’s own immune system turns against the pancreas. Cells meant to protect you start destroying ...

Using an existing steroid-free topical foam daily significantly improved the signs and symptoms of psoriasis on the scalp and ...

Psoriasis can feel all-consuming, but the right strategies and support can make life more manageable when you're going ...

House: Johnson & Johnson has announced new data from the Phase 3 ICONIC-TOTAL study investigating icotrokinra (JNJ-2113), the ...

A large UK Biobank study found that higher consumption of ultra-processed foods (UPFs) is associated with an increased risk ...

Johnson & Johnson (JNJ) posts promising late-stage trial data for plaque psoriasis icotrokinra developed with Protagonist ...

Once-daily roflumilast foam significantly improves scalp and body psoriasis in 8 weeks and was well-tolerated in adolescents ...